FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169249212> ?p ?o ?g. }

• W2169249212 endingPage "709" @default.
• W2169249212 startingPage "695" @default.
• W2169249212 abstract "Objective:The purpose of this prospective study was to evaluate the effects of switching from oral risperidone to flexibly dosed oral paliperidone extended-release (ER) in Brazilian adults with schizophrenia because of lack of efficacy, intolerability, or nonadherence after a minimum trial of 30 days on adequate (labeled) doses of oral risperidone, according to individual clinical judgment.Research design and methods:Subjects with Positive and Negative Syndrome Scale total scores above 78, and/or intolerable adverse effects, with risperidone received open-label paliperidone ER 3 to 12 mg daily for 26 (main phase) to 52 (extension phase) weeks.Clinical trial registration:Clinicaltrials.gov identifier: NCT01010776.Results:The intent-to-treat (efficacy) populations comprised 213 subjects in the main phase and 159 in the extension phase. Of 213 subjects with baseline and post-baseline efficacy data, 154 (72.3%) switched from risperidone to paliperidone ER because of a lack of efficacy and 59 (27.7%) because of tolerability issues, according to individual clinical judgment. Paliperidone ER significantly (p < 0.0500) improved a broad spectrum of efficacy endpoints from baseline, as early as the first post-baseline visit (Visit 2; 4 weeks) and persisting through 26 to 52 weeks. On most efficacy endpoints, function improved from baseline to the first post-baseline visit (week 4) and remained significantly improved compared to baseline at each visit for paliperidone ER treatment, at weeks 8, 13, 26, 39, 26, and 52; data are reported herein mainly for 26 and 52 weeks compared to baseline. Significant improvements from baseline were observed for the Positive and Negative Syndrome Scale total score and subscale scores (each p < 0.0001 at 26 and 52 weeks vs. baseline); and personal and social functioning (p < 0.0001 at 26 and 52 weeks). Paliperidone ER also significantly improved health-related quality of life (Short-Form 36) from baseline, particularly on the Mental Component Summary (p = 0.0011 at 26 weeks and p = 0.0019 at 52 weeks). Treatment with paliperidone ER also significantly improved (vs. baseline) sleep quality (according to decreases on the Pittsburgh Sleep Quality Index; p < 0.0001 at each visit vs. baseline) and disease severity (Clinical Global Impression–Severity; p < 0.0001 at each visit vs. baseline). Paliperidone ER was well tolerated. Adverse events occurring in at least 10% of subjects in either phase were insomnia (14.9% in the main phase and 8.8% in the extension phase); increased body weight (10.7% and 12.6%, respectively); and anxiety (10.7% and 2.5%). Most of these adverse events were: 1) rated as mild or moderate; 2) did not prompt interventions such as paliperidone ER dose adjustment or interruption; and 3) decreased in frequency from the main to the extension phase.Conclusions:Oral paliperidone ER is a rational treatment alternative for patients with schizophrenia whose antipsychotic regimens are switched because of unsuccessful treatment with oral risperidone according to individual clinical judgment. Study limitations included the open-label study design, lack of placebo, and use of subjective clinical judgment to determine lack of efficacy, intolerability, or nonadherence with oral risperidone." @default.
• W2169249212 created "2016-06-24" @default.
• W2169249212 creator A5003640904 @default.
• W2169249212 creator A5009387163 @default.
• W2169249212 creator A5026866861 @default.
• W2169249212 creator A5030843613 @default.
• W2169249212 creator A5036025904 @default.
• W2169249212 creator A5039000554 @default.
• W2169249212 creator A5051124680 @default.
• W2169249212 creator A5056261739 @default.
• W2169249212 creator A5064926027 @default.
• W2169249212 creator A5068841533 @default.
• W2169249212 creator A5070451382 @default.
• W2169249212 creator A5072398977 @default.
• W2169249212 creator A5081598579 @default.
• W2169249212 creator A5084364321 @default.
• W2169249212 creator A5085753285 @default.
• W2169249212 creator A5088535499 @default.
• W2169249212 creator A5089189420 @default.
• W2169249212 date "2013-12-16" @default.
• W2169249212 modified "2023-10-01" @default.
• W2169249212 title "Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study" @default.
• W2169249212 cites W1963580478 @default.
• W2169249212 cites W1979700184 @default.
• W2169249212 cites W1997478537 @default.
• W2169249212 cites W1998327293 @default.
• W2169249212 cites W1998796817 @default.
• W2169249212 cites W2047861786 @default.
• W2169249212 cites W2066361244 @default.
• W2169249212 cites W2077828370 @default.
• W2169249212 cites W2081417197 @default.
• W2169249212 cites W2081878543 @default.
• W2169249212 cites W2101937376 @default.
• W2169249212 cites W2107832369 @default.
• W2169249212 cites W2112820425 @default.
• W2169249212 cites W2131658797 @default.
• W2169249212 cites W2140606211 @default.
• W2169249212 cites W2154942897 @default.
• W2169249212 cites W2159155203 @default.
• W2169249212 cites W4237806337 @default.
• W2169249212 cites W4244847179 @default.
• W2169249212 doi "https://doi.org/10.1185/03007995.2013.869201" @default.
• W2169249212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24289141" @default.
• W2169249212 hasPublicationYear "2013" @default.
• W2169249212 type Work @default.
• W2169249212 sameAs 2169249212 @default.
• W2169249212 citedByCount "6" @default.
• W2169249212 countsByYear W21692492122015 @default.
• W2169249212 countsByYear W21692492122016 @default.
• W2169249212 countsByYear W21692492122023 @default.
• W2169249212 crossrefType "journal-article" @default.
• W2169249212 hasAuthorship W2169249212A5003640904 @default.
• W2169249212 hasAuthorship W2169249212A5009387163 @default.
• W2169249212 hasAuthorship W2169249212A5026866861 @default.
• W2169249212 hasAuthorship W2169249212A5030843613 @default.
• W2169249212 hasAuthorship W2169249212A5036025904 @default.
• W2169249212 hasAuthorship W2169249212A5039000554 @default.
• W2169249212 hasAuthorship W2169249212A5051124680 @default.
• W2169249212 hasAuthorship W2169249212A5056261739 @default.
• W2169249212 hasAuthorship W2169249212A5064926027 @default.
• W2169249212 hasAuthorship W2169249212A5068841533 @default.
• W2169249212 hasAuthorship W2169249212A5070451382 @default.
• W2169249212 hasAuthorship W2169249212A5072398977 @default.
• W2169249212 hasAuthorship W2169249212A5081598579 @default.
• W2169249212 hasAuthorship W2169249212A5084364321 @default.
• W2169249212 hasAuthorship W2169249212A5085753285 @default.
• W2169249212 hasAuthorship W2169249212A5088535499 @default.
• W2169249212 hasAuthorship W2169249212A5089189420 @default.
• W2169249212 hasConcept C118552586 @default.
• W2169249212 hasConcept C126322002 @default.
• W2169249212 hasConcept C159110408 @default.
• W2169249212 hasConcept C197934379 @default.
• W2169249212 hasConcept C203092338 @default.
• W2169249212 hasConcept C2776412080 @default.
• W2169249212 hasConcept C2777126507 @default.
• W2169249212 hasConcept C2778375690 @default.
• W2169249212 hasConcept C2779727114 @default.
• W2169249212 hasConcept C2779951463 @default.
• W2169249212 hasConcept C2780057945 @default.
• W2169249212 hasConcept C2780135775 @default.
• W2169249212 hasConcept C2908997079 @default.
• W2169249212 hasConcept C535046627 @default.
• W2169249212 hasConcept C71924100 @default.
• W2169249212 hasConceptScore W2169249212C118552586 @default.
• W2169249212 hasConceptScore W2169249212C126322002 @default.
• W2169249212 hasConceptScore W2169249212C159110408 @default.
• W2169249212 hasConceptScore W2169249212C197934379 @default.
• W2169249212 hasConceptScore W2169249212C203092338 @default.
• W2169249212 hasConceptScore W2169249212C2776412080 @default.
• W2169249212 hasConceptScore W2169249212C2777126507 @default.
• W2169249212 hasConceptScore W2169249212C2778375690 @default.
• W2169249212 hasConceptScore W2169249212C2779727114 @default.
• W2169249212 hasConceptScore W2169249212C2779951463 @default.
• W2169249212 hasConceptScore W2169249212C2780057945 @default.
• W2169249212 hasConceptScore W2169249212C2780135775 @default.
• W2169249212 hasConceptScore W2169249212C2908997079 @default.
• W2169249212 hasConceptScore W2169249212C535046627 @default.
• W2169249212 hasConceptScore W2169249212C71924100 @default.

• next